Nonalcoholic fatty liver disease. Fatty (change of) liver, not elsewhere classified
Conditions
Interventions
Intervention 1: Intervention group (n = 60): Low-calorie diet and physical activity design based on the Adult Overweight and Obesity Control Guide (published by the US National Heart, Lung, and Blood
Sponsors
Vice-chancellor for research Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 65 Years
Inclusion criteria
Inclusion criteria: Desire to participate in studying and signing consent Evidence of hepatic steatosis in liver ultrasonography (grade 1 to 3 fatty liver) Increased liver enzymes than normal (AST> 38 and ALT> 40 for men and AST> 31 and ALT> 33 for women) BMI in the range of 25-40 kg / m2 aged between 20 and 65 years
Exclusion criteria
Exclusion criteria: Unwillingness to participate in the study Secondary conditions that lead to hepatic steatosis, including: alcohol consumption, hereditary disorders affecting liver status (hemochromatosis and Wilson's disease), and known autoimmune disease Other chronic and acute liver diseases and disorders such as hepatitis, cirrhosis, celiac disease, diabetes, thyroid disorders, cardiovascular, renal, pulmonary and inflammatory diseases (rheumatism) History of taking hepatotoxic drugs (methotrexate, amiodarone, tamoxifen, nifedipine, corticosteroids, valproate and antiviral drugs) as well as anticoagulants such as aspirin Use of any nutritional supplement in the past two months Use of weight-loss drugs over the past two months Having a severe weight loss diet (more than 10% weight loss) over the past three months smoking Pregnancy or lactation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Malondialdehyde. Timepoint: Before intervention and 8 weak after intervention. Method of measurement: Colorimetric method.;Total Antioxidant Capacity. Timepoint: Before intervention and 8 weak after intervention. Method of measurement: Colorimetric method.;High sensitivity C-reactive protein. Timepoint: Before intervention and 12 weak after intervention. Method of measurement: Turbidometric method. | — |
Secondary
| Measure | Time frame |
|---|---|
| Systolic blood pressure. Timepoint: Before intervention and 8 weak after intervention. Method of measurement: Mercury barometric.;Diastolic blood pressure. Timepoint: Before intervention and 8 months after intervention. Method of measurement: Mercury barometric.;Weight. Timepoint: Before intervention and 8 months after intervention. Method of measurement: Scales.;Waist. Timepoint: Before intervention and 8 months after intervention. Method of measurement: Meter.;Hip circumference. Timepoint: Before intervention and 8 months after intervention. Method of measurement: Meter.;Waist to hip ratio. Timepoint: Before intervention and 8 months after intervention. Method of measurement: calculation.;Body fat percentage. Timepoint: Before intervention and 8 months after intervention. Method of measurement: inbody.;BMI. Timepoint: Before intervention and 8 months after intervention. Method of measurement: calculation.;Quality of Life. Timepoint: Before intervention and 8 months after intervention. Method of measurement: SF-36 questionnaire.;Sleep quality. Timepoint: Before intervention and 8 months after intervention. Method of measurement: The Pittsburgh Sleep Quality questionnaire.;Appetite. Timepoint: Before intervention and 8 months after intervention. Method of measurement: CNAQ questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Nahid Aryaeian
Iran University of Medical Sciences
Outcome results
None listed